Search
forLearn
5 / 801 resultslearn HT-B
learn 18β-glycyrrhetinic acid
learn ferrous lactate
learn APISCALP™
Research
5 / 283 resultsresearch Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Modern Management Approaches for Alopecia Areata
Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
research Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Mice without the vitamin D receptor have bone issues and other health problems, suggesting vitamin D is important for preventing various diseases in humans.
Community Join
5 / 1000+ resultscommunity Pérdida de cabello en jóvenes (15-20 años) mi experiencia.
A 19-year-old shares his hair loss experience and treatment routine, which includes 1mg finasteride daily, 2mg oral minoxidil daily, ketoconazole shampoo every 2 days, and a healthy lifestyle. He notes that oral minoxidil is showing better results than topical minoxidil.
community 3,5 months of only topical minoxidil
A 24-year-old reported new hair growth on temples after 3.5 months of using topical minoxidil without shedding. They plan to add finasteride to maintain progress, as minoxidil alone may not be enough long-term.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Are we still getting the PP405 phase 2a results by the end of March?
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.